Abatacept (Orencia)
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ANCA-associated Vasculitis
Conditions
ANCA-associated Vasculitis
Trial Timeline
Nov 1, 2007 → Nov 1, 2008
NCT ID
NCT00482066About Abatacept (Orencia)
Abatacept (Orencia) is a phase 2 stage product being developed by Bristol Myers Squibb for ANCA-associated Vasculitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00482066. Target conditions include ANCA-associated Vasculitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00482066 | Phase 2 | Terminated |
Competing Products
3 competing products in ANCA-associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| rituximab + Placebo | Roche | Phase 3 | 77 |
| CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids | Amgen | Phase 2 | 51 |
| Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine | Amgen | Phase 3 | 76 |